Fosun Pharma Subsidiary Passes GMP Compliance Inspection

Stock News06-17 17:00

Fosun Pharma (SHSE: 600196) has announced that its controlling subsidiary, Shanghai Henlius Biopharmaceutical Co., Ltd., recently received a "Drug GMP Compliance Inspection Notification Letter" from the Shanghai Drug Administration.

The notification confirms that the subsidiary's production base in Songjiang District, Shanghai, has passed a Good Manufacturing Practice compliance inspection for Pertuzumab Injection (marketed in China under the brand name Hanbeiyou®).

The scope of the inspection covered the Drug Substance production East Line, the Drug Product production line, and the packaging line.

Passing this GMP compliance inspection signifies that the related production facilities for Pertuzumab Injection now meet the standards outlined in the Good Manufacturing Practice for Drugs, laying a foundation for the commercial production and supply of this drug within China.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1174291047?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-17 17:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1174291047","market":"us","top_or_hot":-1,"title":"Fosun Pharma Subsidiary Passes GMP Compliance Inspection","media":"Stock News","content":"<p><b>Fosun Pharma</b> (<b>SHSE: 600196</b>) has announced that its controlling subsidiary, Shanghai Henlius Biopharmaceutical Co., Ltd., recently received a \"Drug GMP Compliance Inspection Notification Letter\" from the Shanghai Drug Administration.<br><br>The notification confirms that the subsidiary's production base in Songjiang District, Shanghai, has passed a Good Manufacturing Practice compliance inspection for Pertuzumab Injection (marketed in China under the brand name Hanbeiyou®).<br><br>The scope of the inspection covered the Drug Substance production East Line, the Drug Product production line, and the packaging line.<br><br>Passing this GMP compliance inspection signifies that the related production facilities for Pertuzumab Injection now meet the standards outlined in the Good Manufacturing Practice for Drugs, laying a foundation for the commercial production and supply of this drug within China.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fosun Pharma Subsidiary Passes GMP Compliance Inspection</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFosun Pharma Subsidiary Passes GMP Compliance Inspection\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-06-17 17:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Fosun Pharma</b> (<b>SHSE: 600196</b>) has announced that its controlling subsidiary, Shanghai Henlius Biopharmaceutical Co., Ltd., recently received a \"Drug GMP Compliance Inspection Notification Letter\" from the Shanghai Drug Administration.<br><br>The notification confirms that the subsidiary's production base in Songjiang District, Shanghai, has passed a Good Manufacturing Practice compliance inspection for Pertuzumab Injection (marketed in China under the brand name Hanbeiyou®).<br><br>The scope of the inspection covered the Drug Substance production East Line, the Drug Product production line, and the packaging line.<br><br>Passing this GMP compliance inspection signifies that the related production facilities for Pertuzumab Injection now meet the standards outlined in the Good Manufacturing Practice for Drugs, laying a foundation for the commercial production and supply of this drug within China.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"","article_id":"1174291047","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1174291047","pubTimestamp":1781686827,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Fosun Pharma (SHSE: 600196) has announced that its controlling subsidiary, Shanghai Henlius Biopharmaceutical Co., Ltd., recently received a \"Drug GMP Compliance Inspection Notification Letter\" from...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600196":"复星医药","BK0239":"医药制造","BK0028":"国家队","BK0187":"一线龙头","BK0183":"MSCI概念","02196":"复星医药","BK0096":"民营医院","BK1515":"抗疫概念","BK1191":"制药","BK0188":"融资融券","BK0012":"证金概念","BK0175":"白马股","BK1593":"医美概念股","BK0196":"行业龙头","BK0060":"抗癌"},"translate_title":"复星医药子公司通过GMP合规性检查","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":1,"02196":1},"content_text":"Fosun Pharma (SHSE: 600196) has announced that its controlling subsidiary, Shanghai Henlius Biopharmaceutical Co., Ltd., recently received a \"Drug GMP Compliance Inspection Notification Letter\" from the Shanghai Drug Administration.The notification confirms that the subsidiary's production base in Songjiang District, Shanghai, has passed a Good Manufacturing Practice compliance inspection for Pertuzumab Injection (marketed in China under the brand name Hanbeiyou®).The scope of the inspection covered the Drug Substance production East Line, the Drug Product production line, and the packaging line.Passing this GMP compliance inspection signifies that the related production facilities for Pertuzumab Injection now meet the standards outlined in the Good Manufacturing Practice for Drugs, laying a foundation for the commercial production and supply of this drug within China.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"executive","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1174291047","isCrawlerRequest":true}